State-of-the-science of patient navigation as a strategy for enhancing minority clinical trial accrual.
State-of-the-science of patient navigation as a strategy for enhancing minority clinical trial accrual.
复制标题
DOI：
10.1002/cncr.28570
复制
发表时间：
2014-04-01
期刊：
影响因子：
6.2
通讯作者：
Ford, Jean G.
中科院分区：
文献类型：
--
作者：
Ghebre, Rahel G.;Jones, Lovell A.;Wenzel, Jennifer A.;Martin, Michelle Y.;Durant, Raegan W.;Ford, Jean G.
患者导航计划正在兴起，旨在解决医疗服务不足的人群（包括少数种族/族裔）在临床试验参与方面的差异。然而，对于患者导航员在临床试验过程中的作用以及评估项目有效性的结果指标缺乏共识。对 PubMed、Medline、CINHAL 和其他来源的文献进行了回顾，以确定临床试验中患者导航的定性和定量研究。检索产生了 212 项研究，其中只有 12 项符合本次审查的条件。符合条件的研究报告了癌症临床试验中患者导航计划的制定，包括在非裔美国人、美洲印第安人和夏威夷原住民中的培训和实施。据报道，参加患者导航计划的患者拒绝临床试验的比例较低，为 4% 至 6%。然而，很少有研究报告患者导航对增加临床治疗试验注册人数的功效。提出结果措施以协助开发和评估旨在增加癌症临床试验参与的患者导航计划的功效和/或有效性。未来的研究需要评估患者导航器在解决参与临床试验的障碍和增加医疗服务不足的癌症患者的入学率方面的功效。
Patient navigation programs are emerging, that aim to address disparities in clinical trial participation among medically underserved populations, including racial/ethnic minorities. However, there is a lack of consensus on the role of patient navigators within the clinical trial process, as well as outcome measures to evaluate program effectiveness. A review of the literature was conducted of PubMed, Medline, CINHAL, and other sources to identify qualitative and quantitative studies on patient navigation in clinical trials. The search yielded 212 studies, of which only 12 were eligible for this review. The eligible studies reported on development of programs for patient navigation in cancer clinical trials, including training and implementation among African American, American Indian and Native Hawaiians. Low clinical trial refusal, 4% to 6%, was reported among patients enrolled in patient navigation program. However, few studies reported on the efficacy of patient navigation on increasing clinical treatment trial enrollment. Outcome measures are proposed to assist in developing and evaluating the efficacy and/or effectiveness of patient navigation programs that aim to increase participation in cancer clinical trials. Future research is needed to evaluate the efficacy of patient navigators in addressing barriers to clinical trial participation and increasing enrollment among medically underserved cancer patients.
登录
查看更多内容
影响因子：
6.2
作者：
Battaglia TA;Burhansstipanov L;Murrell SS;Dwyer AJ;Caron SE;Prevention and Early Detection Workgroup, National Patient Navigation Leadership Summit
通讯作者：
Prevention and Early Detection Workgroup, National Patient Navigation Leadership Summit
影响因子：
6.2
作者：
Natale-Pereira A;Enard KR;Nevarez L;Jones LA
通讯作者：
Jones LA
影响因子：
6.2
作者：
Guadagnolo, B. Ashleigh;Boylan, Amy;Sargent, Michele;Koop, David;Brunette, Deb;Kanekar, Shalini;Shortbull, Vanessa;Molloy, Kevin;Petereit, Daniel G.
通讯作者：
Petereit, Daniel G.
影响因子：
6.2
作者：
Jean-Pierre, Pascal;Fiscella, Kevin;Winters, Paul C.
通讯作者：
Winters, Paul C.
DOI：
10.1353/cpr.0.0037
发表时间：
2008-01-01
期刊：
Progress in community health partnerships : research, education, and action
影响因子：
--
作者：
Braun, Kathryn L;Allison, Amanda;Tsark, Joann U
通讯作者：
Tsark, Joann U